Valeant's Pipeline Star Potiga Gets FDA Approval for Seizures
By Trista Morrison
Tuesday, June 14, 2011
Six months after receiving a complete response letter for epilepsy drug Potiga (ezogabine), Valeant Pharmaceuticals International Inc. and partner GlaxoSmithKline plc gained approval of the potassium channel opener as an adjunctive treatment for partial-onset seizures.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.